| Full text | |
| Author(s): |
McNeill Ingham, Sheila Jean
[1, 2]
;
Pochini, Alberto de Castro
[1, 3]
;
de Oliveira, Daniel Antonio
[1, 3]
;
Garcia Lisboa, Bianca Cristina
[4]
;
Beutel, Abram
[4]
;
Valero-Lapchik, Valderez Bastos
[4]
;
Ferreira, Ana Maria
[5]
;
Abdalla, Rene Jorge
[1, 3]
;
Cohen, Moises
[1, 3]
;
Han, Sang Won
[6, 4]
Total Authors: 10
|
| Affiliation: | [1] Univ Fed Sao Paulo, Dept Orthopaed Surg, Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Dept Phys Med & Rehabil, Sao Paulo - Brazil
[3] Univ Fed Sao Paulo, Ctr Sports Med, Sao Paulo - Brazil
[4] Univ Fed Sao Paulo, Ctr Gene Therapy, Sao Paulo - Brazil
[5] Univ Fed Fluminense, Ctr Med Sci, Sch Vet, Rio De Janeiro - Brazil
[6] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo - Brazil
Total Affiliations: 6
|
| Document type: | Journal article |
| Source: | PM&R; v. 3, n. 12, p. 1106-1109, DEC 2011. |
| Web of Science Citations: | 7 |
| Abstract | |
Objective: To evaluate the effect of bupivacaine on muscle force and histology. We hypothesize that bupivacaine will worsen the muscle's physiological activity. Setting: Controlled laboratory experiment. Methods: Bupivacaine (0.5 mL, 0.5%) was injected into the mid belly and distal portions of the right gastrocnemius in 32 Wistar male rats (the left gastrocnemius was used as a control). After 5, 14, 21, and 28 days, in groups of 4, muscle force was evaluated and the animals were euthanized by an overdose of anesthetic for histologic evaluation. One-way analysis of variance was used to analyze data from force and weight measurements. Only the values of P < .05 were considered to be statistically significant. Results: Bupivacaine causes a process of degeneration-regeneration of the muscle fibers and it also causes a reduction in muscle force, which is significant at 2 and 3 weeks and does not normalize at 4 weeks. The muscle injury is obvious after 5 days, and the degenerative process is predominant at 2 and 3 weeks. We found an increase in muscle mass in the acute phase and a decrease in muscle force. Conclusion: Although our results do not allow a direct clinical application, we believe that caution should be warranted when intramuscular bupivacaine is used. PM R 2011;3:1106-1109 (AU) | |
| FAPESP's process: | 11/00859-6 - Role of GM-CSF in the repair of muscule injury: gene therapy for muscle injuries |
| Grantee: | Sang Won Han |
| Support Opportunities: | Regular Research Grants |